1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2

Catherine A. Shu(Columbia University Irving Medical Center), Keiko Goto(National Cancer Center Hospital East), Yuichiro Ohe(National Cancer Center Hospital East), Benjamin Besse(Institut Gustave Roussy), K. Park(Samsung Medical Center), Y. Wang(Sichuan University), Frank Griesinger(Carl von Ossietzky Universität Oldenburg), James Chih‐Hsin Yang(National Taiwan University Hospital), Enriqueta Felip(Vall d'Hebron Hospital Universitari), Rachel E. Sanborn(Providence Portland Medical Center), R. Bernabe Caro(Hospital Universitario Virgen del Rocío), Joshua Bauml(University of Pennsylvania), J. Chen(Janssen (United States)), E. Fennema(Janssen (United States)), James Mahoney(Janssen (United States)), Leonardo Trani(Janssen (United States)), Roland E. Knoblauch(Janssen (United States)), Meena Thayu(Janssen (United States)), Byoung Chul Cho(Yonsei University)
Annals of Oncology
September 1, 2021
Cited by 20

Abstract


Related Papers

No related papers found

Powered by citation graph analysis